Evidence map›Paper›PMID 33712885›Full record

ArticleCellular and molecular neurobiology2022

Changes in the Brain Extracellular Matrix Composition in schizophrenia: A Pathophysiological Dysregulation and a Potential Therapeutic Target.

Daniela Rodrigues-Amorim, Tania Rivera-Baltanás, Patricia Fernández-Palleiro, Marta Iglesias-Martínez-Almeida, Luis Freiría-Martínez, Cynthia Jarmardo-Rodriguez, María Del Carmen Vallejo-Curto, María Álvarez-Ariza, Marta López-García, Elena de Las Heras and 3 more

Open access · greenAbstract read
In one paragraph

Article in Cellular and molecular neurobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Peptide Electrostatic Modulation Directs Human Neural Cell Fate.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Nidogen in development and disease.Frontiers in cell and developmental biology · 2024
    Review
  11. Article
  12. Review
  13. Article
  14. Transcriptomic and Proteomic Analysis of CRISPR/Cas9-MediatedInternational journal of molecular sciences · 2022
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Daniela Rodrigues-Amorim *Translational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, CIBERSAM, Hospital Álvaro Cunqueiro, Bloque Técnico, Planta 2, Sala de Investigación, Estrada Clara Campoamor, 341, 36212, Vigo, Spain.ORCID http://orcid.org/0000-0002-0469-0534
Tania Rivera-Baltanás *Translational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, CIBERSAM, Hospital Álvaro Cunqueiro, Bloque Técnico, Planta 2, Sala de Investigación, Estrada Clara Campoamor, 341, 36212, Vigo, Spain.ORCID http://orcid.org/0000-0002-3723-6039
Patricia Fernández-PalleiroTranslational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, CIBERSAM, Hospital Álvaro Cunqueiro, Bloque Técnico, Planta 2, Sala de Investigación, Estrada Clara Campoamor, 341, 36212, Vigo, Spain.
Marta Iglesias-Martínez-AlmeidaTranslational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, CIBERSAM, Hospital Álvaro Cunqueiro, Bloque Técnico, Planta 2, Sala de Investigación, Estrada Clara Campoamor, 341, 36212, Vigo, Spain.ORCID http://orcid.org/0000-0002-9131-8617
Luis Freiría-MartínezTranslational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, CIBERSAM, Hospital Álvaro Cunqueiro, Bloque Técnico, Planta 2, Sala de Investigación, Estrada Clara Campoamor, 341, 36212, Vigo, Spain.ORCID http://orcid.org/0000-0002-9177-0988
Cynthia Jarmardo-RodriguezTranslational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, CIBERSAM, Hospital Álvaro Cunqueiro, Bloque Técnico, Planta 2, Sala de Investigación, Estrada Clara Campoamor, 341, 36212, Vigo, Spain.
María Del Carmen Vallejo-CurtoTranslational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, CIBERSAM, Hospital Álvaro Cunqueiro, Bloque Técnico, Planta 2, Sala de Investigación, Estrada Clara Campoamor, 341, 36212, Vigo, Spain.
María Álvarez-ArizaTranslational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, CIBERSAM, Hospital Álvaro Cunqueiro, Bloque Técnico, Planta 2, Sala de Investigación, Estrada Clara Campoamor, 341, 36212, Vigo, Spain.
Marta López-GarcíaTranslational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, CIBERSAM, Hospital Álvaro Cunqueiro, Bloque Técnico, Planta 2, Sala de Investigación, Estrada Clara Campoamor, 341, 36212, Vigo, Spain.
Elena de Las HerasTranslational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, CIBERSAM, Hospital Álvaro Cunqueiro, Bloque Técnico, Planta 2, Sala de Investigación, Estrada Clara Campoamor, 341, 36212, Vigo, Spain.
Alejandro García-CaballeroTranslational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, CIBERSAM, Hospital Álvaro Cunqueiro, Bloque Técnico, Planta 2, Sala de Investigación, Estrada Clara Campoamor, 341, 36212, Vigo, Spain.ORCID http://orcid.org/0000-0001-5714-8266
José Manuel OlivaresTranslational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, CIBERSAM, Hospital Álvaro Cunqueiro, Bloque Técnico, Planta 2, Sala de Investigación, Estrada Clara Campoamor, 341, 36212, Vigo, Spain. jose.manuel.olivares.diez@sergas.es.ORCID http://orcid.org/0000-0003-0784-9720
Carlos SpuchTranslational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, CIBERSAM, Hospital Álvaro Cunqueiro, Bloque Técnico, Planta 2, Sala de Investigación, Estrada Clara Campoamor, 341, 36212, Vigo, Spain. cspuch@uvigo.es.ORCID http://orcid.org/0000-0002-9161-0124
Universidade de Vigo · ESUniversity Hospital Complex Of Vigo · ES

Funding

Axencia Galega de Innovación IN606A-2019/025Axencia Galega de Innovación IN607B 2018/17Axencia Galega de Innovación IN607C-2017/02Fundação para a Ciência e a Tecnologia SFRH/BD/135623/2018Instituto de Salud Carlos III P16/00405Ministerio de Sanidad, Servicios Sociales e Igualdad 2017I054
6 · The paper itself

Abstract

The brain extracellular matrix (ECM) is involved in crucial processes of neural support, neuronal and synaptic plasticity, extrasynaptic transmission, and neurotransmission. ECM is a tridimensional fibrillary meshwork composed of macromolecules that determine its bioactivity and give it unique characteristics. The characterization of the brain ECM is critical to understand its dynamic in SZ. Thus, a comparative study was developed with 71 patients with schizophrenia (SZ) and 70 healthy controls. Plasma of participants was analysed by label-free liquid chromatography-tandem mass spectrometry, and the results were validated using the classical western blot method. Lastly, immunostaining of post-mortem human brain tissue was performed to analyse the distribution of the brain ECM proteins by confocal microscopy. The analysis identified four proteins: fibronectin, lumican, nidogen-1, and secreted protein acidic and rich in cysteine (SPARC) as components of the brain ECM. Statistical significance was found for fibronectin (P = 0.0166), SPARC (P = 0.0003), lumican (P = 0.0012), and nidogen-1 (P < 0.0001) that were decreased in the SZ group. Fluorescence imaging of prefrontal cortex (PFC) sections revealed a lower expression of ECM proteins in SZ. Our study proposes a pathophysiological dysregulation of proteins of the brain ECM, whose abnormal composition leads to a progressive neuronal impairment and consequently to neurodegenerative processes due to lack of neurophysiological support and dysregulation of neuronal homeostasis. Moreover, the brain ECM and its components are potential pharmacological targets to develop new therapeutic approaches to treat SZ.

Indexed as

FibronectinsSchizophreniaBrainExtracellular MatrixExtracellular Matrix ProteinsHumansLumicanOsteonectinExtracellular Matrix ProteinsFibronectinsLumicanOsteonectinBrain ECMFibronectinLumicanNidogen-1SchizophreniaSPARC

Identifiers

PMID33712885
PMCPMC11421689
OpenAlexW3135255324

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.